Honoring the life of Dulcina DeBerry
Black History Month: Huntsville trailblazer who opened doors and turned pages for African Americans in the 1940s
Black History Month: Honoring the life of Dulcina DeBerry By Kellie Miller | February 11, 2021 at 5:56 PM CST - Updated February 12 at 8:52 AM
HUNTSVILLE, Ala. (WAFF) - In the 1900s, educational resources for African Americans were scarce. But Dulcina DeBerry, educator and librarian, worked hard to fight those inequities and eventually opened the first public library for African Americans in Madison County.
âShe was a very compassionate person. She was a scholar, she loved to learnâ¦and she was a problem solver,â said Shalis Worthy, Archivist at the Huntsville-Madison County Public Library.
Mara-Salvatrucha (MS-13) Gang Member Arrested near Refugio, Texas
Release Date: February 11, 2021
CORPUS CHRISTI, Texas – Corpus Christi Border Patrol Station (CCT) agents arrested a Mara Salvatrucha (MS-13 gang) member from of El Salvador.
Yesterday morning, CCT agents responded to a request for assistance from a Texas Department of Public Safety trooper on a traffic stop north of Refugio, Texas. CCT agents arrived on scene and determined the subject was a citizen of El Salvador who was illegally present in the United States. The subject was arrested and transported to the Border Patrol station for processing. During processing, record checks identified the Salvadoran national as a MS-13 gang member. In addition to being a gang member, the subject has criminal convictions for Carrying a Concealed Weapon, Trespassing, and was previously ordered removed from the country in 2005.
MedCity News
Amicus’s path to unseat Sanofi in rare disease gets steeper after Phase 3 miss
Amicus Therapeutics CEO John Crowley said the totality of data support the Pompe disease therapy’s submission to the FDA. That rolling application is on track for completion in the second quarter.
Shares1
Amicus Therapeutics aims to position its experimental Pompe disease treatment as the new standard of care, supplanting a therapy from Sanofi. But securing approval will require explaining to regulators why they should look past the treatment’s failure to achieve the main goal of a pivotal study.
The main goal of the Phase 3 study testing the Amicus drug, AT-GAA, was to measure how much further, on average, patients could walk in a six-minute test after 52 weeks of treatment. Pompe patients have an inherited enzyme deficiency that leads to a progressive weakening of their muscles.